Vonlerolizumab

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameVonlerolizumab

Drug Alias NamePogalizumabRO-7021608RG-7888MOXR-0916

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonists

TargetsTumor necrosis factor receptor superfamily member 4

Therapy Area/IndicationsCarcinoma, Transitional CellNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[8]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGenentech Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesGenentech Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Transitional CellNeoplasms

ATC CodeN/A